Eph receptor tyrosine kinase inhibitor

SI-7534

Eph receptor tyrosine kinase inhibitor, >98% (HPLC)

IUPAC Name : N-(3-((4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-5-(trifluoromethyl)phenyl)-5-(thiophen-2-yl)nicotinamide

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is a next‑generation analog produced through a structure‑guided optimization campaign repurposing human kinase inhibitors for malaria. It exhibits superior antimalarial activity and selectivity, outperforming the original EphA2‑targeted lead. Its profile supports applications in Plasmodium biology, resistance‑driven malaria research, and medicinal‑chemistry programs exploring kinase‑derived antiparasitic scaffolds.

References : Wong L. et al.: J. Med. Chem., 67(2), 1460-1480, 2024.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.